

# Curriculum Vitae

## Harold Malcolm HUDSON

### Business Address:

Department of Statistics, DEFS,  
Macquarie University, NSW 2109, AUSTRALIA  
FAX: 61-2-9850-7669  
e-mail: Malcolm.Hudson@mq.edu.au

### Qualifications

B.Sc. with Hons. 1 in Mathematics,  
University of N.S.W., 1970

Ph.D. in Statistics, Stanford University, 1974.  
Thesis title: Empirical Bayes Estimation.  
Thesis supervisors: Lincoln Moses, Charles Stein.

### Appointments

2008 – present Emeritus Professor, Faculty of Science  
Macquarie University  
2008 – present Honorary Professor, Faculty of Medicine  
University of Sydney

### Honours and Awards

IEEE Marie Sklodowska-Curie Award (co-recipient with Brian F. Hutton,  
Lawrence A. Shepp), Institute of Electrical and Electronic Engineers,  
2014.

Elected member, International Statistical Institute, 2001

Award, Institute of Electrical and Electronic Engineers, 2001.

## **PROFESSIONAL ACTIVITIES**

### **Clinical Medicine**

Chair, Data Scientific Monitoring Board (DSMB),  
Impact of Aldosterone Antagonism on Cardiac Function in Dia-  
betic Cardiomyopathy,  
Principal Investigators: Dr Melissa Leung, Prof. Dominic Leung  
Member, ANZ Breast Cancer Trials Group, 2002 – present

### **Referee**

Australian J. Statistics,  
Computational Statistics and Data Analysis,

### **Supervision of Postgraduate Students**

Dr. P. Blinman,  
Ph.D., 2011, University of Sydney (co-supervisor).

Dr. R. O'Connell,  
Ph.D., 2011, Macquarie University (co-supervisor).

Ms. Z. Liu,  
Ph.D., 2010, Macquarie University (co-supervisor).

Ms. L. Li,  
Ph.D. submission, 2009, Macquarie University (primary supervisor).

### **External Grants**

2008-2010

Cancer Australia Priority-driven Collaborative Research Scheme  
Chief investigator (with M. Barton, G. Delaney). \$503,415 (offer 28  
May 2008).

2003-2007 National Health and Medical Research Council, Program Grant:  
Clinical Trials Centre, University of Sydney, \$7.5 million (Principal  
Investigator, CIs J. Simes, A Keeche, V. GebSKI, I. Marschner)

**PUBLICATIONS****Invited seminars**

Invited presentation, Statistical Society of Australia, NSW Branch:

July 2015,

August 2009

Invited speaker, R workshop, ASC-2008 satellite

Sydney, July, 2008

Invited speaker, ARCS symposium,

Sydney, July, 2007

**Journal Articles (refereed)**

- [c1] P Blinman, B Hughes, C Crombie, T Christmas, M Hudson et al. Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: what makes it worthwhile? *European Journal Of Cancer*, 2015. (accepted for publication 19/5/2015).
- [c2] H.M. Hudson, S.N. Lô, R.J. Simes, A.M. Tonkin and S. Heritier . Semiparametric methods for multistate survival models in randomised trials. *Statistics in Medicine*, 33(10):1621–1645, May 2014.
- [c3] Peter Fox, Malcolm Hudson, Chris Brown, Sarah Lord, Val GebSKI, Paul DeSouza, and Chee Khoon Lee. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. *British Journal of Cancer*, 109:147–153, 2013.
- [c4] C.K. Lee, H.M. Hudson, M. Stockler, A.S. Coates, S. Ackland, V. GebSKI, S. Lord, M. Friedlander, F. Boyle, and R.J. Simes. A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. *Breast Cancer Research and Treatment*, 129(2):467–476, 2011.
- [c5] Malcolm Hudson. Book review: Analysing Seasonal Health Data by Adrian G. Barnett and Annette J. Dobson. *Australian and New Zealand Journal of Statistics*, 53(3), 2011. Article first published online : 19 JUL 2011.
- [c6] M.B. Barton, H.M. Hudson, G. Delaney, P. Gruver, and Z. Liu. Patterns of retreatment by radiotherapy. *Clinical Oncology*, 23:10–18, 2011. doi:10.1016/j.clon.2010.09.013.
- [c7] P. Blinman, V. Duric, A.K. Nowak, P. Beale, S. Clarke, K. Briscoe, A. Boyce, D. Goldstein, M. Hudson, and M. Stockler. Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile? *European Journal Of Cancer*, 46(10):1800–1807, 2010. Accepted 23 December, 2009. In press. doi:10.1016/j.ejca2009.12.032.

- [c8] Malcolm Hudson and Jun Ma. On asymptotic convergence of the block-iterative Fisher scoring algorithm. *Statistics and Probability Letters*, 80(11-12):922 – 925, 2010.
- [c9] Peter S. Grimison, R. John Simes, H. Malcolm Hudson, and Martin R. Stockler. Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancer. *Value in Health*, 12:967 – 976, 2009. Published Online: Mar 16 2009 DOI: 10.1111/j.1524-4733.2009.00536.x.
- [c10] P.S. Grimison, R.J. Simes, H.M. Hudson, and M.R. Stockler. Deriving utility measures from a health-related quality-of-life questionnaire for comparing treatments in cancer trials. *Value in Health*, 12:800 – 807, 2009. Published Online: Mar 11 2009 2:27AM. DOI: 10.1111/j.1524-4733.2009.00505.x.
- [c11] R. O’Connell and M. Hudson. Risk of mortality after acute myocardial infarction: performance of model updating methods for application in different geographical regions. *Computational Statistics and Data Analysis*, 2009. (<http://dx.doi.org/10.1016/j.csda.2008.08.016>).
- [c12] S. Lo, S. Heritier, and M. Hudson. Saddlepoint approximation for semi-Markov processes with application to a cardiovascular randomized study. *Computational Statistics and Data Analysis*, (53):683–698, 2009. (Special Issue in Clinical Trials).
- [c13] J. Ma and M. Hudson. Block-iterative Fisher scoring algorithms for maximum penalized likelihood image reconstruction in emission tomography. *IEEE Trans. Med. Imaging*, 27(8):1130–1142, 2008.

#### Conference Proceedings (refereed)

- [e1] P Blinman, B Hughes, C Crombie, T Christmas, M Hudson, et al (on behalf of the Australasian Lung Cancer Trials Group (ALTG)). Preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: what makes it worthwhile? ;. In *5th Australian Lung Cancer Conference; 1518 Aug 2014; Brisbane*, 2014.
- [e2] H.M. Hudson. Semi-parametric methods for multi-state survival models in randomized trials. Poster presentation., August 2013. ISCB2013: 34th Annual Conference of the International Society for Clinical Biostatistics, Munich.
- [e3] C. Crombie, T. Christmas, M. Hudson et al. Patients’ preferences for adjuvant chemotherapy (ACT) in early non-small cell lung cancer (NSCLC): what makes it worthwhile? Poster, October 2013. World Lung Conference, Sydney.

- [e4] M. Hudson, C. Brown, A.S. Veillard et al. Lung cancer clinicians' preferences for adjuvant chemotherapy (ACT) in non-small cell lung cancer (NSCLC): what makes it worthwhile? Poster presentation, 2013. 15th World Conference on Lung Cancer.
- [e5] Chee Khoon Lee, Alan Coates, Malcolm Hudson, Karin Ribbi, and Jrg Bernhard. Prognostic significance of qualityoflife scores in early stage and relapsed breast cancer: results from seven randomized trials of the international breast cancer study group. Poster presentation, 2013. 2013 San Antonio Breast Cancer Symposium, December 1014, 2013.
- [e6] Sue-Anne McLachlan, Brett Hughes, Catherine Crombie, Tim Christmas, Malcolm Hudson, et al. Patients' and their doctors preferences for adjuvant chemotherapy (ACT) in early non-small cell lung cancer (NSCLC): What makes it worthwhile? PACT study. Abstract and Presentation slides, 2012. COSA-IPOS conference, Brisbane, 2012 (session: Best of the Best - Oral - Health Services).
- [e7] M. Hudson, M. Barton, et al. Age-Cohort Models for Recurrent Events in Longitudinal Studies. In *ISCB 2011, Ottawa*. August 2011. Presentation slides.
- [e8] M. Hudson, S. Lo, and S. Heritier. Semi-parametric methods for survival estimation in semi-Markov models of randomized trials. In *ISCB 2010: 29 August – 2 September, 2010, Montpellier, France*. August 2010. Presentation slides.
- [e9] H. Malcolm Hudson. Power comparisons of parametric and rank tests: grouped outcomes with zero-spike. In R.S. Anderssen, R.D. Braddock, and L.T.H. Newham, editors, *Proceedings of the 18th World IMACS Congress and MODSIM09 International Congress on Modelling and Simulation*, pages 143–149. Modelling and Simulation Society of Australia and New Zealand and International Association for Mathematics and Computers in Simulation, 2009. (ISBN: 978-0-9758400-7-8. [http://www.mssanz.org.au/modsim09/A2/hudson\\_hm.pdf](http://www.mssanz.org.au/modsim09/A2/hudson_hm.pdf). Refereed.).
- [e10] Prunella Blinman, Vlatka Duric, et al. Patients' preferences for adjuvant chemotherapy (ACT) in early colon cancer (ECC): What makes it worthwhile. In *American Society of Clinical Oncology Annual Meeting*, 2008. (abs, poster accepted in the general gastrointestinal session, MH conducted statistical analyses).